UK markets closed
NIKKEI 225
38,179.46 -49.65 (-0.13%) HANG SENG
19,115.06 +151.38 (+0.80%) CRUDE OIL
79.19 +0.93 (+1.19%) GOLD FUTURES
2,344.30 -30.70 (-1.29%) DOW
39,431.51 -81.33 (-0.21%) Bitcoin GBP
50,272.21 +1,393.95 (+2.85%)
PFE May 2024 26.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:20PM EDT. Market open.
| Previous close | 0.0200 |
| Open | 0.0200 |
| Bid | 0.0000 |
| Ask | 0.0100 |
| Strike | 26.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0100 - 0.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 25.58k |
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksModerna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
PR NewswireAstellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the cou
© 2024 Yahoo. All rights reserved.